The concept of non-inferiority for comparing treatment with different anti-VEGF agents for wet AMD using mean BCVA changes from baseline was probably first introduced in the CATT study [6] and also adopted in the IVAN study [7]. Here, VEGFA is linked to wet macular degeneration.